Chimeric antigen receptor (CAR) T cell–based therapies offer a novel approach to cancer therapy. Thy use genetically engineered T cells to specifically target tumor cells. CAR T cells are generated from patient-derived T cells (autologous) or from healthy donors (allogenic). After enrichment and genetic modification T cells are expanded ex vivo and reinfused into the patient where the CAR T cells bind to the specific surface antigen and kill the tumor cell.
To develop such therapies, it is necessary identify CAR T cell targets and the suitable starting cell subset (e.g. α/β T cells, γ/δ T cells). Furthermore, CAR safety, specificity, and efficacy are analyzed and improved before novel CAR T cells are verified in several mouse models.
Our goal is it to support you at every step of the way. We simplify the translation of your research workflow using RUO products into GMP manufacturing using the CliniMACS Prodigy® in combination with MACS® GMP Reagents.
Seems like you are coming from USA!
Do you want to visit our website in your country?